Monday, July 11, 2011
Prolor Biotech has received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering the company’s CTP platform, which has the potential to extend the duration of activity of virtually all therapeutic proteins. The allowed claims cover CTP-modified compositions of a wide array of classes of therapeutic proteins, including hormones, high affinity protein ligands, proteins that induce or regulate an immune response, proteins that are involved with autocrine and paracrine activities and mimetics of these therapeutic proteins, as well as other types of proteins.
“Allowance of this new patent is of great importance for PROLOR’s intellectual property portfolio, since it covers a very wide array of therapeutic proteins and extends the patent protection around our CTP platform for many years,” said Shai Novik, president of Prolor.
This new U.S. patent is expected to issue in the next few months.